Goldman sold 1.3 million Valeant shares backing loan to CEO, Valeant says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Goldman sold 1.3 million Valeant shares backing loan to CEO, Valeant says
November 6, 2015 12:19 PM EST
Valeant Pharma (NYSE: VRX) is pushing to the highs of the session, following earlier news that about 1.3 million shares CEO Mike Pearson had pledged on a loan were sold yesterday due to margins calls.
The news suggests that some of the... More
November 6, 2015 9:02 AM EST
PDL BioPharma (NASDAQ: PDLI) issued financial results for the third quarter on Wednesday, November 4, 2015 and has subsequently received numerous inquiries on its reported royalties from royalty rights it acquired from Depomed, Inc. (Depomed). Specifically, the nature of the questions were about royalties for Glumetza® (metformin HCL extended-release tablets), which is currently marketed and sold by Valeant Pharmaceuticals International, Inc. (Valeant).
Background
When PDL acquired the Depomed royalty rights in October 2013, Glumetza was sold and marketed by Santarus, Inc. (Santarus). In January 2014, Salix Pharmaceuticals, Inc. (Salix) acquired Santarus and assumed responsibility for... More
